O
EPRX

OrbiMed’s Eupraxia Pharmaceuticals EPRX Stock Holding History

OrbiMed’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
+269,000
New +$1.85M 0.03% 125

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

OrbiMed's EPRX Position: Q2 2026 in Review

OrbiMed opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 269,000 shares worth $1.78M. The stake represents 0.03% of the portfolio and ranks #125 among its holdings.

68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • OrbiMed held 269,000 shares of Eupraxia Pharmaceuticals worth $1.78M as of Q2 2026.
  • Eupraxia Pharmaceuticals was a new OrbiMed position in Q2 2026.
  • Eupraxia Pharmaceuticals made up 0.03% of OrbiMed's portfolio in Q2 2026, its #125 holding.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.